Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 20/20 | 0.77 |
| ▸ | AKT2 | P31751 | 15/20 | 0.77 |
| ▸ | AKT3 | Q9Y243 | 14/20 | 0.77 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.71 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.71 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.71 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.71 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30574929 | 1.00 | AKT1 (0.77) | AKT1AKT2AKT3CYP3A4CYP2D6 | |
| SCHEMBL30574827 | 0.91 | AKT1 (0.80) | AKT1AKT2AKT3CYP3A4CYP2D6 | |
| SCHEMBL25385750 | 0.91 | AKT1 (0.80) | AKT1AKT2AKT3CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL31455629 | 0.90 | AKT1 (0.81) | AKT1AKT2AKT3CYP3A4CYP2D6 | |
| SCHEMBL31544824 | 0.90 | AKT1 (0.79) | AKT1AKT2AKT3CYP3A4CYP2D6 | |
| SCHEMBL26234267 | 0.90 | AKT1 (0.79) | AKT1AKT2AKT3CYP3A4CYP2D6 | |
| SCHEMBL31455356 | 0.89 | AKT1 (0.83) | AKT1AKT2AKT3CYP3A4CYP2D6 | |
| SCHEMBL25385607 | 0.87 | AKT1 (0.85) | AKT1AKT2AKT3CYP3A4CYP2D6 | |
| SCHEMBL2176395 | 0.87 | AKT1 (1.00) | AKT1AKT2AKT3CYP3A4CYP2D6 | |
| SCHEMBL31455137 | 0.87 | AKT1 (0.71) | AKT1AKT2AKT3CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250115600-A1 | COVALENT MODIFIERS OF AKT1 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. | 2025-04-10 | — | — | US | disclosed |
| WO-2023168291-A1 | COVALENT MODIFIERS OF AKT1 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. (US) | 2023-09-07 | — | — | WO | disclosed |
| WO-2023168291-A1 | COVALENT MODIFIERS OF AKT1 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. (US) | 2023-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250115600-A1 | COVALENT MODIFIERS OF AKT1 AND USES THEREOF | AKT1, AKT1S1, AKT2 | AKT1 1/4885AKT2 3/4885AKT3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.